title: Alarming arbitrariness in EU prescription and reimbursement criteria for anti-dementia drugs.
authors.forename: Richard C
authors.initials: RC
authors.lastname: Oude Voshaar
authors.forename: Alistair
authors.initials: A
authors.lastname: Burns
authors.forename: Marcel G M
authors.initials: MG
authors.lastname: Olde Rikkert
mesh_terms: D002800:Cholinesterase Inhibitors / Q000600:supply & distribution* / Q000627:therapeutic use; D003704:Dementia / Q000188:drug therapy*; D000077265:Donepezil; D015259:Dopamine Agents / Q000600:supply & distribution / Q000627:therapeutic use; D005062:European Union; D005702:Galantamine / Q000600:supply & distribution / Q000627:therapeutic use; D006801:Humans; D007189:Indans / Q000600:supply & distribution / Q000627:therapeutic use; D008559:Memantine / Q000600:supply & distribution / Q000627:therapeutic use; D018377:Neurotransmitter Agents / Q000600:supply & distribution* / Q000627:therapeutic use; D048448:Phenylcarbamates / Q000600:supply & distribution / Q000627:therapeutic use; D010880:Piperidines / Q000600:supply & distribution / Q000627:therapeutic use; D012051:Reimbursement Mechanisms; D000068836:Rivastigmine
chemical_list: D002800:Cholinesterase Inhibitors; D015259:Dopamine Agents; D007189:Indans; D018377:Neurotransmitter Agents; D048448:Phenylcarbamates; D010880:Piperidines; D005702:Galantamine; D000077265:Donepezil; D000068836:Rivastigmine; D008559:Memantine